Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: The next revolution in coronary intervention?

Heart

Volumn 99, Issue 17, 2013, Pages 1236-1241

  Patel, Niket ^a   Banning, Adrian P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPIC ACID DERIVATIVE; MACROGOL; MAGNESIUM; RAPAMYCIN; SALICYLIC ACID ADIPIC ACID SALICYLIC ACID TRIMER; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BARE METAL STENT; BIODEGRADABLE IMPLANT; BIOSORPTION; CLINICAL TRIAL (TOPIC); COMPOSITE MATERIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; EQUIPMENT DESIGN; FEASIBILITY STUDY; HUMAN; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS DEVELOPMENT; PROCESS TECHNOLOGY; PROSTHESIS MATERIAL; RETURN OF SPONTANEOUS CIRCULATION; REVIEW; THROMBOSIS; TREATMENT RESPONSE; VASOMOTOR REFLEX;

CORONARY ARTERY DISEASE; CORONARY PHYSIOLOGY; INTERVENTIONAL CARDIOLOGY;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; TISSUE SCAFFOLDS;

EID: 84881479633     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303346     Document Type: Review

References (48)

1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48. (Pubitemid 47393576)
2. Wentzel JJ, Whelan DM, van der Giessen WJ, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000;33:1287-95. (Pubitemid 30427325)
3. Maier W. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circ 2002;105:2373-7. (Pubitemid 34556388)
4. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42. (Pubitemid 352001347)
5. Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009;120:141-9.
6. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-8.
7. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010;56: S43-78.
8. Di Mario C, Borgia F. Assimilating the current clinical data of fully bioabsorbable stents. EuroIntervention 2009;5(Suppl F):F103-8.
9. Waksman R. The disappearing stent: when plastic replaces metal. Circulation 2012;125:2291-4.
10. Ormiston J, Serruys PWS. Bioabsorbable coronary stents. Circ Cardiov Interv 2009;2:255-60.
11. Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol 2009;57:537-65.
12. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-40.
13. Garg S, Serruys P. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2010;8:449-70.
14. Palmerini T, Biondi-Zoccai G, Riva DD, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.
15. Onuma Y, Piazza N, Ormiston JASP. Everolimus-eluting bioabsorbable stent-Abbot Vascular programme. EuroIntervention 2009;5(Suppl F):F98-102.
16. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.
17. Stone G, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel- eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery. Circ 2009;119:680-6.
18. Serruys PW, Ruygrok P, Neuzner J, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006;2:286-94.
19. Tsuchida K, Piek JJ, Neumann F, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 2005;1:266-72.
20. Spuentrup E, Ruebben A, Mahnken A, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circ 2005;111:1019-26. (Pubitemid 40354520)
21. Mahnken AH. CT imaging of coronary stents: past, present, and future. ISRN Cardiol 2012;2012:139823.
22. Erbel R, Böse D, Haude M, et al. [Absorbable coronary stents. New promising technology]. Herz 2007;32:308-19. (Pubitemid 47047278)
23. Nishio S, Kosuga K, Igaki K, et al. Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012;125:2343-53.
24. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102:399-404. (Pubitemid 30490677)
25. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75. (Pubitemid 46829357)
26. Haude M, Erbel R, Verheye S, et al. Comparison of intermediate term late lumen loss after coronary implantation of bare or paclitaxel eluting absorbable metal scaffolds: results from progress-ams and biosolve-1 trials. J Am Coll Cardiol 2012;59(Suppl E):E203.
27. Haude M, Erbel R, Verheye S, et al. Twelve-month clinical and angiographic results of the multicenter first-in-man BIOSOLVE-1 study with the paclitaxel-eluding bioabsorbable magnesium scaffold. EuroIntervention 2012;8(Suppl N):N215.
28. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907. (Pubitemid 351384734)
29. Koolen J, Erbel R, Verheye S, et al. Six and twelve-month greyscale and virtual histology IVUS results with the drug eluting absorbable metal scaffold in the BIOSOLVE-I study. EuroIntervention 2012;8(Suppl N):N216.
30. Waksman R, Erbel R, Di Mario C, et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiov Interv 2009;2:312-20.
31. Haude M, Erbel R, Erne P, et al. Two-Year Clinical Data of Cohort 1 and Multi-modality Imaging Results up to 1-Year Follow-up of the BIOSOLVE-I Study with the Paclitaxel- Eluting Bioabsorbable Magnesium Scaffold (DREAMS). Presented at: TCT October 2012.
32. Yan JBV. Elixir Medical's bioresorbable drug eluting stent (BDES) programme: an overview. EuroIntervention 2009;5:80-2.
33. Verheye S. Multicenter First-in-Man Evaluation of the Myolimus-Eluting Bioresorbable Coronary Scaffold: 6-month Imaging and 12-month Clinical Results. Presented at: TCT October 2012.
34. Pollman MJ. Engineering a bioresorbable stent: REVA programme update. EuroIntervention 2009;5(Suppl F):F54-7.
35. Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. Presented at euroPCR 2009.
36. Costa RA. REVA ReZolve Clinical Program Update. Presented at: TCT October 2012.
37. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Cathet Cardiovasc Interv 2008;72:186-94.
38. Jabara R. Poly-anhydride based on salicylic acid and adipic acid anhydride. Presented at: EuroPCR 2009.
39. Dudek D, Onuma Y, Ormiston J, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2012;7:1060-1.
40. Onuma Y, Nieman K, Webster M, et al. TCT-37 five-year clinical outcomes and non-invasive angiographic imaging results with functional assessment after bioresorbable everolimus-eluting scaffold implantation in patients with de novo coronary artery disease. J Am Coll Cardiol 2012;60(Suppl B):B11.
41. Okamura T, Garg S, Gutiérrez-Chico JL, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010;5:932-8.
42. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-88.
43. Dudek D. ABSORB cohort B trial evaluation of the absorb everolimus eluting bioresorbable vascular scaffold (Absorb BVS) in the treatment of patients with de novo native coronary artery lesions: 2-year clinical results. J Am Coll Cardio 2012;59 (13s1):E319.
44. Banning A. ABSORB clinical programme- the latest! Presented at: euroPCR 2012.
45. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therap. Euro Heart J 2012;33:1325-33.
46. Bartorelli AL. ABSORB EXTEND: An Interim Report on the 6-month clinical outcome from the first 500 patients registered. Presented at TCT 2012.
47. Bartorelli AL. ABSORB EXTEND: An Interim Report on the 12-Month Clinical Outcomes from the First 250 Patients Registered. Presented at TCT 2012.
48. Cottone RJ, Thatcher GL, Parker SP, et al. OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. EuroIntervention 2009;5 (Suppl F):F65-71.